Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–12 of 12 results
Advanced filters: Author: Keith B. Elkon Clear advanced filters

  • Although autoantibodies occur in healthy individuals, pathogenic autoantibodies are the key etiologic agent in many autoimmune diseases in humans, most notably lupus erythematosus. In this Review the authors explore how these autoantibodies become pathogenic, what accounts for their specificity, how they cause disease and whether they have a clinical role as biomarkers of disease.

    • Keith Elkon
    • Paolo Casali
    Reviews
    Nature Clinical Practice Rheumatology
    Volume: 4, P: 491-498

  • Transcription factors known for handling the body's response to lipids promote clearance of apoptotic cells by macrophages, according to new research (pages 1266–1272). When this process goes awry, autoimmunity can result.

    • Keith B Elkon
    News & Views
    Nature Medicine
    Volume: 15, P: 1246-1248

  • Necrosis induces inflammation, but how necrotic cells signal to immune cells was poorly understood. New work by Chen et al. shows that IL-1α acts as a mediator, translating a signal from the necrotic cells to induce the recruitment of immune cells to the site of injury (pages 851–856).

    • Keith B Elkon
    News & Views
    Nature Medicine
    Volume: 13, P: 778-780

  • A number of cytokine pathways are important in the disease process of SLE, and several biological agents for SLE have been developed that target different cytokines or their receptors. This Review discusses the rationale for the use of anticytokine therapies in SLE, reviews the different agents tested to date, and presents future directions for therapy.

    • Lars Rönnblom
    • Keith B. Elkon
    Reviews
    Nature Reviews Rheumatology
    Volume: 6, P: 339-347

  • Exactly how nucleic acids trigger type I interferon responses via certain Toll-like receptors has been uncertain. Now, a new pathway involving gene products previously linked to systemic lupus erythematosus but not known to interact has been unravelled, which could be of relevance to the female sex bias in this disease.

    • Keith B. Elkon
    • Tracy A. Briggs
    News & Views
    Nature Reviews Rheumatology
    Volume: 16, P: 543-544

  • Sensing of cytosolic DNA by cyclic GMP–AMP synthase (cGAS) is central to the pathogenesis of a number of autoinflammatory syndromes and possibly some autoimmune diseases, such as systemic lupus erythematosus (SLE). Activation of cGAS signalling requires its deacetylation, so might aspirin have therapeutic potential to treat SLE by acetylating cGAS?

    • Keith B. Elkon
    News & Views
    Nature Reviews Rheumatology
    Volume: 15, P: 254-255

  • The cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway not only is involved in host defence against infection but can lead to immune dysregulation. Here, the authors examine the biology and biochemistry of cGAS–STING and discuss its role in disease and potential approaches to therapeutic targeting.

    • Sladjana Skopelja-Gardner
    • Jie An
    • Keith B. Elkon
    Reviews
    Nature Reviews Nephrology
    Volume: 18, P: 558-572